Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03951415
Other study ID # DOMEC
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date July 8, 2019
Est. completion date August 1, 2021

Study information

Verified date March 2021
Source Leiden University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The DOMEC trial is designed as a Dutch Gynecological Oncology Group (DGOG), prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer or carcinosarcoma of the uterus to investigate the efficacy of the combination therapy of olaparib tablets and durvalumab IV.


Description:

The prognosis of recurrent or persistent endometrial carcinoma not amenable to local therapy is poor. First line therapy exists of platinum-based chemotherapy or hormonal therapy. No standard subsequent-line therapy has been described.The combination of Poly(ADP-ribose) polymerases (PARP) inhibition and Programmed death-ligand 1 (PD-L1) blocking has great potential in the treatment of recurrent endometrial cancer. The DOMEC trial is designed to investigate this treatment combination among all molecular subgroups. The DOMEC trial is designed as a DGOG, prospective, multi-center, phase II study for 55 patients with advanced (recurrent, refractory or metastatic) endometrial cancer, including carcinosarcoma of the uterus. Patients must have had one prior platinum-based chemotherapeutic regimen or not be able/willing to get chemotherapy. The aim is to investigate the efficacy of the combination therapy of olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks in terms of progression free survival. Secondary objectives are to investigate objective response rate, overall survival, safety and predictive biomarkers.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 55
Est. completion date August 1, 2021
Est. primary completion date August 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria: - Written informed consent - Age > 18 years old - Histologically confirmed diagnosis of endometrial cancer or carcinosarcoma of the endometrium. - Metastatic disease or locally advanced tumor not amenable to local therapy. - Documented progressive disease before enrolment. - Measurable lesions outside irradiated field or progressive measurable lesions in irradiated area - Not eligible for hormonal therapy (because of negative hormone receptor/poor differentiation, or after failure of hormonal therapy). - Previous failure of chemotherapy, or refusal to undergo chemotherapy or chemo-naive patients not suitable for chemotherapy. - WHO performance 0-1 - Adequate organ system function as measured within 28 days prior to administration of study treatment, as defined below: - Haemoglobin = 10.0 g/dL, with no blood transfusion in the past 28 days. - Absolute neutrophil count (ANC) = 1.5 x 109/L - Platelet count = 100 x 109/L - Total bilirubin = 1.5 x institutional upper limit of normal (ULN) (not applicable to Gilbert's syndrome) - Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) = 2.5 x ULN unless liver metastases are present in which case they must be = 5x ULN - Patients must have creatinine clearance estimated of =51 mL/min estimated using the Cockcroft-Gault equation or 24 hr urine clearance. - Life expectancy of at least 16 weeks. - Measurable disease as defined by RECIST 1.1 criteria - Able to swallow and retain oral medication. - A female is eligible to enter and participate in this study if there is: Exclusion criteria: - Participation in another clinical study with an investigational product during the last month or previous enrolment in the present study. - Any previous treatment with PARP inhibitor, including olaparib and/or any previous treatment with a PD1 or PD-L1 inhibitor - History of another primary malignancy except for malignancy treated with curative intent and with no known active disease =5 years before the first dose of investigational product and of low potential risk for recurrence or adequately treated non-melanoma skin cancer, lentigo maligna or carcinoma in situ. - History of leptomeningeal carcinomatosis, symptomatic uncontrolled brain metastases (=2mg/ day corticosteroids started =4 weeks prior to treatment is accepted) and spinal cord compression (unless received definitive treatment and clinically stable for 28 days) . - Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome - Concomitant use of known strong or moderate CYP3A inhibitors and inducers. - Any unresolved toxicity NCI CTCAE Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. - Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (except intranasal and inhaled corticosteroids or systemic prednisone = 10 mg/day) - Major surgery =2 weeks of starting study treatment - History of active primary immunodeficiency - Active or prior documented autoimmune or inflammatory disorders, with exception of: vitiligo or alopecia, hypothyroidism stable on hormone replacement, any chronic skin condition that does not require systemic therapy, celiac disease controlled by diet alone - Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. - Active infection including tuberculosis, hepatitis B/C and HIV - Patients with an expected or known hypersensitivity to olaparib or durvalumab or any of the excipients of the products. - Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). - Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. - Pregnancy or breastfeeding

Study Design


Intervention

Drug:
PARP inhibitor and Anti-PD-L1
olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks

Locations

Country Name City State
Netherlands Amsterdam UMC, AMC Amsterdam
Netherlands NKI-AVL Amsterdam
Netherlands Universitair Medisch Centrum Groningen Groningen
Netherlands Leiden University Medical Center Leiden
Netherlands Academisch Ziekenhuis Maastricht Maastricht
Netherlands RadboudMC Nijmegen
Netherlands Erasmus MC Rotterdam
Netherlands Universitair Medisch Centrum Utrecht Utrecht

Sponsors (9)

Lead Sponsor Collaborator
Leiden University Medical Center Amsterdam University Medical Center, AstraZeneca, Erasmus Medical Center, Maastricht University Medical Center, Radboud University, The Netherlands Cancer Institute, UMC Utrecht, University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Functional HRD assay (optional) Extra biopsy At baseline
Other Immunological effects of PARP-1 inhibition (optional) Tests for T cell and APC functionality measured by the measurement of recall antigen responses and mixed lymphocyte cultures, respectively, the levels of regulatory T cells, activation markers on T cells and DC). Change From Baseline to 6 weeks and 12 weeks
Other Predictive biomarkers for PD-L1 blocking in blood (optional) e.g. monocyticMDSC levels, DC levels, inhibitory marker expression, neutrophil-to-lymphocyte ratio, absolute lymphocyte count, T-cell reactivity during PD-L1 blocking, T-cell cytokine expression after SEB activation Change From Baseline to 6 weeks and 12 weeks
Primary Progression free survival (PFS) PFS will be counted from the date of registration until the first observation of radiological progressive disease according to RECIST 1.1 criteria or death due to any cause, whichever occurred first. 6 months
Secondary Objective response rate (ORR) according to RECIST 1.1 criteria 12 weeks
Secondary Overall survival (OS) OS will be determined from the date of registration until death from any cause. Through study completion, up to 36 months
Secondary Adverse events Assessed by NCI Common Terminology Criteria for adverse Events (CTCAE) version 5.0 Through study completion, up to 36 months
Secondary Predictive biomarkers in tumor biopsy MMRd/POLE, HR status, quantification of CD3,CD4,CD8,CD103,CD161,PD-1,LAG3,CTLA-4,NKG2A,GOXp3 positieve T cells, NK cells, percentage PD-L1 on myeloid cells/tumorcells, quantification of myeloid cell infiltration (CD68,CD14,CD33,CD163) in tumor biopsies. At baseline
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06409039 - POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Active, not recruiting NCT05682950 - Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 2
Not yet recruiting NCT05974995 - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer N/A
Recruiting NCT03291106 - Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
Recruiting NCT03291275 - Survival Outcomes of Uterine Malignancies in Chinese Population N/A
Completed NCT00341458 - Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
Terminated NCT05067972 - A Study of PF-07260437 in Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05795244 - Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) Phase 2
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Active, not recruiting NCT04865289 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study Phase 3
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Completed NCT01460979 - Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma Phase 2
Active, not recruiting NCT05869123 - Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 1/Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Active, not recruiting NCT05588076 - Endometrial Lesions Predictions